(Reuters) – Medical tool manufacturer Dexcom beat Wall Street approximates for third-quarter profits on Thursday, aided by durable need for its constant sugar screens for diabetic issues individuals.
However, the business stated its full-year sales projection of regarding $4 billion to $4.05 billion, sending its shares decreases virtually 16% after the bell.
Dexcom claimed Chief Commercial Officer Teri Lawver would certainly retire at the end of the year.
The business in July lowered its yearly profits projection, criticizing a restructuring of its sales group, less clients, and reduced profits from each consumer, sending its shares to a four-year reduced. Shares are down 40% until now this year.
Dexcom reported third-quarter profits of $994.2 million, defeating experts’ price quotes of $990.7 million, according information from LSEG.
(Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila)
